General Clinical Chemistry Analyzers and Accessories
Abcam Alvespimycin (17-DMAG) hydrochloride, 100MG
MW 653.2 Da, Purity >99%. A potent Hsp90 inhibitor (IC₅₀ = 62 nM), can bind to the ATP-binding motif and inhibit the protein chaperoning activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ispinesib (SB-715992), 100MG
MW 517.1 Da, Purity >98%. A potent, selective and reversible allosteric inhibitor of KSP with IC₅₀ value of 0.5 nM. Often combines with chemotherapy drugs to tumor treatment.
The product is subject to the following: Abcam Restricted Use Statement
Abcam P 22077, 10MG
MW 315.3 Da, Purity >98%. Selective USP7 (IC₅₀ = 8 μM) inhibitor. Active against closely related USP47. Selective versus SENP2c0re (IC₅₀ >50 μM) and DENI (IC₅₀ >50 μM). Destabilizes Claspin. Inhibits neuroblastoma growth by inducing p53-mediated apoptosis. Inhibits Tip60 deubiquitination.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ticagrelor, P2Y12 receptor antagonist, 10MG
MW 522.6 Da, Purity >98%. Reversible antagonist of the platelet purinergic P2Y12 receptor, the main receptor responsible for ADP-induced platelet aggregation. Changes the conformation of the P2Y12 receptor, resulting in reversible, concentration dependent inhibition of the receptor.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ponesimod, sphingosine-1-phophate receptor agonist, 10MG
MW 461 Da. Ponesimod is a potent agonist of sphingosine-1-phophate receptor. (S1P₁/EDG-1; IC₅₀s = 6, >10,000, 2,068, 1,956, and 142 nM for S1P₁-S1P₅, respectively, in a radioligand binding assay). Selectively activates S1P₁ in a GTPγS assay (EC₅₀s = 5.7, >10,000, 105, 1,108, and 59.1 nM, for S1P₁-S1P₅, respectively).
The product is subject to the following: Abcam Restricted Use Statement
Abcam G10, STING signaling activator, 10MG
MW 430.9 Da, Purity >98%. G10 is an indirect activator or stimulator of interferon genes (STING) signaling. It induces transcription of genes dependent on IRF3 and IFN, which are activated by STING, but has no effect on non-STING activated NF-κB-dependent transcription of IL-8, IL-1β, or MIP-1α in human fibroblasts. However, G10 does increase expression of NF-κB-dependent genes in human peripheral blood mononuclear cells (PBMCs) and human umbilical microvascular endothelial cells (HUMECs). In vitro, it prevents replication of the chikungunya and Venezuelan equine encephalitis alphaviruses (IC₉₀s = 8.01 and 24.57 μM, respectively). G10 (100 μM) increases phosphorylation of IRF3, which is lost in cells lacking STING.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ponesimod, sphingosine-1-phophate receptor agonist, 5MG
MW 461 Da. Ponesimod is a potent agonist of sphingosine-1-phophate receptor. (S1P₁/EDG-1; IC₅₀s = 6, >10,000, 2,068, 1,956, and 142 nM for S1P₁-S1P₅, respectively, in a radioligand binding assay). Selectively activates S1P₁ in a GTPγS assay (EC₅₀s = 5.7, >10,000, 105, 1,108, and 59.1 nM, for S1P₁-S1P₅, respectively).
The product is subject to the following: Abcam Restricted Use Statement
Abcam Daclatasvir (BMS-790052), HCV NS5A protein inhibitor, 10MG
MW 738.9 Da, Purity =97%. Daclatasvir a potent, direct acting, small molecule inhbitor of HCV NS5A protein. It inhbibits replicons expressing a wide range of HCV genotypes with EC₅₀ values in the pM range (9 and 71 pM against the 1b and 2a genotypes, respectively). It also inhibits infection by the JFH-1 genotype 2a virus in cultured cells. Daclatasvir is thought to inhibit relication of the HCV viral genome by affecting the subcellular localization of HCV NS5A and preventing its incorporation into relication complexes. In HCV-infected Huh7 cells, Daclatasvir (1 nM) inhibits viral RNA synthesis and viron assembly. Daclatasvir displays moderate activity against the OAT1B1 (IC₅₀ = 1.5 μM) and OAT1B3 (IC₅₀ = 3.27 μM) organic anion transporters.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Narciclasine, Rho/LIM kinase/cofilin signaling pathway activator, 5MG
MW 307.25 Da, Purity >98%. Plant growth regulator originally isolated from Narcissus bulbs. Exhibits antiproliferative and pro-apoptotic effects in carcinoma cells and displays cytotoxic activity against a panel of 60 cancer cell lines (mean IC₅₀ = 47 nM). Activity decreases rate of cell division and increases mitosis duration in vitro. Also modulates the Rho/ROCK/LIM kinase/cofilin pathway; stimulates RhoA activation and induces actin polymerization.
The product is subject to the following: Abcam Restricted Use Statement
Abcam RITA, p53 activator, 25MG
MW 292.4 Da, Purity >98%. p53 activator. Tricyclic thiophene derivative that binds to p53 and induces its accumulation in tumor cells. Prevents p53-HDM2 (MDM2) interaction in vitro and in vivo and affects p53 interaction with several negative regulators. Induces expression of p53 target genes and apoptosis in various tumor cell lines expressing wild-type p53.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Apatinib, 25MG
MW 441.9 Da. Potent and selective inhibitor of VEGFR2, IC₅₀ = 1 nm. Orally bioavailable. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Capivasertib (AZD5363), 100MG
MW 428.9 Da, Purity >95%. A novel pyrrolopyrimidine derivative. A potent inhibitor of all AKT isoforms, IC₅₀ <10 nM, with potential antineoplastic activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GSK2656157, 5MG
MW 416.5 Da, Purity >=98%. Potent and selective PERK inhibitor (IC₅₀ = 0.9 nM in cell-free assay). ATP-competitive. Exibits 500-fold selectivity for PERK versus a panel of 300 kinases.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GSK2656157, 25MG
MW 416.5 Da, Purity >=98%. Potent and selective PERK inhibitor (IC₅₀ = 0.9 nM in cell-free assay). ATP-competitive. Exibits 500-fold selectivity for PERK versus a panel of 300 kinases.
The product is subject to the following: Abcam Restricted Use Statement
Abcam ML 204, TRPC4 blocker, 25MG
MW 226.32 Da. Selective TRPC4 channel blocker (IC₅₀ = 0.96 (fluorescence assay) - 2.6 μM (electrophysiological assay)). Selective versus TRPC6 (19-fold) and TRPC5 (9-fold). Essentially inactive at TRPV1, TRPV3, TRPA1 and TRPM8 channels at concentrations up to 22 μM.
The product is subject to the following: Abcam Restricted Use Statement